SureTrader Advertisement PRTC
Home > Boards > US OTC > Medical - Drugs >

Cellceutix Corporation (CTIX)

CTIX RSS Feed
Add CTIX Price Alert      Hide Sticky   Hide Intro
Moderator: BigKahuna, BooDog, noretreat, TOB, sox040713, TheHound
Search This Board:
Last Post: 5/25/2016 2:33:51 PM - Followers: 702 - Board type: Free - Posts Today: 107

Cellceutix Corporation (CTIX) 
 

 

http://cellceutix.com/
 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@cellceutix.com
 
About Cellceutix: 
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin concluded a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its FDA application for a Phase 2 ovarian cancer study. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol is in a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site atwww.cellceutix.com.

Management:  http://cellceutix.com/team/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://cellceutix.com/pipeline/

 

 
Recent News and Press Releases: 
http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX
 
http://cellceutix.com/category/press-release/

A randomized, double-blind study comparing single-dose and short-course brilacidin to daptomycin in the treatment of acute bacterial skin & skin structure infections (ABSSSI)

http://eccmid.meetingexpert.net/ECCMID_546/poster_122533/program.aspx/anchor122533

Synthetic novel host defense protein mimetics for the treatment of Gram-negative bacterial infections

http://eccmid.meetingexpert.net/ECCMID_546/poster_122353/program.aspx

 
SEC Filings (CIK:0001355250):  http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com/

 
Share Structure:  See SEC filing link above for current share structure
 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet


http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations:  info@cellceutix.com

Following is a WEEKLY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CTIX
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CTIX News: Quarterly Report (10-q) 05/09/2016 05:57:46 PM
CTIX News: Current Report Filing (8-k) 04/08/2016 10:04:54 AM
CTIX News: Current Report Filing (8-k) 03/31/2016 06:24:52 AM
CTIX News: Quarterly Report (10-q) 02/08/2016 04:03:50 PM
CTIX News: Amended Statement of Ownership (sc 13g/a) 01/27/2016 09:57:11 AM
PostSubject
#148787  Sticky Note Cellceutix Phase 2 Trial of Prurisol for Mild sox040713 05/24/16 02:18:08 PM
#148662  Sticky Note Achieving CTIX Potential Catalysts and Past Milestones BooDog 05/24/16 11:06:48 AM
#144039  Sticky Note $CTIX ---> (.)(.) <--- CTIX$ TheHound 03/31/16 03:44:16 PM
#139659  Sticky Note (repost) Court Filings (Zagami vs Cellceutix, 1:15-cv-07194) slcimmuno 02/11/16 08:25:42 AM
#133344  Sticky Note We are looking forward ... to our fiscal noretreat 12/14/15 02:58:59 PM
#117003  Sticky Note Cellceutix released efficacy data for Kevetrin, its cancer TOB 08/09/15 03:05:24 PM
#149001   Yes Leo confirms HLA B57 pts excluded for To infinity and beyond! 05/25/16 02:33:51 PM
#148999   I see your point. The current state of BigKahuna 05/25/16 02:26:26 PM
#148998   A stock buy back? With what money? Maybe septmike09 05/25/16 02:23:34 PM
#148997   keep dreaming - this stock is stuck in MXAMDUD 05/25/16 02:20:12 PM
#148996   I am convinced we will have more big cabel 05/25/16 02:20:05 PM
#148995   So, day traders are struggling to get back BigKahuna 05/25/16 02:15:37 PM
#148994   Agree. Most ,including Leo, felt Prurisol was the farrell90 05/25/16 02:15:27 PM
#148993   not supposed to say MXAMDUD 05/25/16 02:12:19 PM
#148992   What does your sales department contact say about Jhawker 05/25/16 02:09:53 PM
#148991   much bigger news would be Leo announcing a MXAMDUD 05/25/16 02:05:24 PM
#148990   much bigger news would be if any benefit To infinity and beyond! 05/25/16 02:02:16 PM
#148989   only price pays. and currently it isn't paying MXAMDUD 05/25/16 01:58:31 PM
#148988   nice! JUST 10-11-12 05/25/16 01:14:44 PM
#148987   I think it's an educated guess based on sox040713 05/25/16 01:08:02 PM
#148986   My understanding is that patient X was treated sox040713 05/25/16 01:02:19 PM
#148985   Sox Patients prefer purisol. Big winner. Echo20 Echo20 05/25/16 12:53:57 PM
#148984   I love it how the traders complain so rule_rationale 05/25/16 12:41:33 PM
#148983   Does it really matter? Nothing moves this MXAMDUD 05/25/16 12:19:23 PM
#148982   So what's up next for news? B? tombrady12nh 05/25/16 12:16:16 PM
#148981   Must be frustrating watching the price stay too BigKahuna 05/25/16 11:27:15 AM
#148979   yikes - this thing is trading heavy MXAMDUD 05/25/16 11:18:49 AM
#148978   well, per Leo, they plan to explore dermatology arena. JUST 10-11-12 05/25/16 11:11:55 AM
#148977   Thanks sox for some affirmation that I wasn't nerby 05/25/16 11:07:13 AM
#148976   "just sold some on the ask at 1.66 nerby 05/25/16 10:51:34 AM
#148974   slow and steady planting and bashing works more vip1999 05/25/16 10:41:58 AM
#148973   Dud, There's 7000 other investments out there to Rdunn88 05/25/16 10:34:28 AM
#148972   An up is down post followed by another BigKahuna 05/25/16 10:29:02 AM
#148971   10Q says phase 2 proof of concept trial To infinity and beyond! 05/25/16 10:28:48 AM
#148970   this stock is a mess. no positive MXAMDUD 05/25/16 10:25:03 AM
#148969   haven't sold. when is the next potential MXAMDUD 05/25/16 10:23:53 AM
#148968   Up is clearly down with such posts. SP BigKahuna 05/25/16 10:23:51 AM
#148967   Well technically it's been put to rest a septmike09 05/25/16 10:22:41 AM
#148966   $$$$$$$ CTIX is ready to fly tombrady12nh 05/25/16 10:22:20 AM
#148965   you are crazy to sell now, unless you To infinity and beyond! 05/25/16 10:20:52 AM
#148964   From the results, the riskiest IP has been BigKahuna 05/25/16 10:20:22 AM
#148960   Yesterday's data puts the Mako hit-piece to rest... Rdunn88 05/25/16 10:13:26 AM
#148959   Would be nice if a partnership is offered. frrol 05/25/16 10:11:49 AM
#148958   Maybe not but in my view the rear bradfordbros 05/25/16 10:03:30 AM
#148957   The Anacor Phase II results completely sucked, that Waverunner1 05/25/16 10:00:55 AM
#148956   The market doesn't do what we want of frrol 05/25/16 09:59:08 AM
#148955   just sold some on the ask at 1.66 MXAMDUD 05/25/16 09:54:44 AM
#148954   Again, Go back and look at the ANAC chart iclight 05/25/16 09:53:09 AM
#148953   Better yet they may have shorted. bradfordbros 05/25/16 09:53:08 AM
#148952   Some people were hoping for even better results frrol 05/25/16 09:52:09 AM
#148951   Totally agree. There are hit pieces that iclight 05/25/16 09:45:35 AM
#148950   I would like to think yesterday's news and bradfordbros 05/25/16 09:39:25 AM
#148949   Spot on! The whole biotech sector is in dooshbag 05/25/16 09:37:01 AM
#148948   Yes. TheDane 05/25/16 09:29:32 AM
#148947   Yes, our P2 data is better than their luxe 05/25/16 09:29:25 AM
#148946   Of course, you are correct. There reason it TheDane 05/25/16 09:28:56 AM
PostSubject